Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up
暂无分享,去创建一个
Chang-ming Huang | Qing-Feng Chen | Mi Lin | C. Zheng | Ping Li | J. Xie | Jun Lu | R. Tu | M. Lin | L. Cao | Jia‐bin Wang | Qi‐yue Chen | Jian-Xian Lin | Jian-Wei Xie | Chang-ming Huang